Develops drugs for rare neurological diseases, including narcolepsy and epilepsy.
Jun 2026Revenue $960M/yrExpenses $729M/yr
Reached break-even Nov 2020
Figures by year
When did Harmony Biosciences Holdings become profitable?
Its revenue passed its expenses in Nov 2020. In the 12 months to Jun 2026, revenue was $960M and expenses $729M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $868M | $660M | $208M |
| Dec 2024 | $715M | $524M | $191M |
| Dec 2023 | $582M | $390M | $192M |
| Dec 2022 | $438M | $318M | $120M |
| Dec 2021 | $305M | $218M | $87.5M |
| Dec 2020 | $160M | $143M | $17.0M |
| Dec 2019 | $6.00M | $152M | −$146M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.